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Abstract
Background: Self-assembly of the amyloid-β peptide (Aβ) has been implicated in the pathogenesis
of Alzheimer's disease (AD). As a result, synthetic molecules capable of inhibiting Aβ self-assembly
could serve as therapeutic agents and endogenous molecules that modulate Aβ self-assembly may
influence disease progression. However, increasing evidence implicating a principal pathogenic role
for small soluble Aβ aggregates warns that inhibition at intermediate stages of Aβ self-assembly may
prove detrimental. Here, we explore the inhibition of Aβ1–40 self-assembly by serum albumin, the
most abundant plasma protein, and the influence of this inhibition on Aβ1–40 activation of
endothelial cells for monocyte adhesion.
Results: It is demonstrated that serum albumin is capable of inhibiting in a dose-dependent manner
both the formation of Aβ1–40 aggregates from monomeric peptide and the ongoing growth of Aβ1–
40  fibrils. Inhibition of fibrillar Aβ1–40  aggregate growth is observed at substoichiometric
concentrations, suggesting that serum albumin recognizes aggregated forms of the peptide to
prevent monomer addition. Inhibition of Aβ1–40 monomer aggregation is observed down to
stoichiometric ratios with partial inhibition leading to an increase in the population of small soluble
aggregates. Such partial inhibition of Aβ1–40 aggregation leads to an increase in the ability of resulting
aggregates to activate endothelial cells for adhesion of monocytes. In contrast, Aβ1–40 activation of
endothelial cells for monocyte adhesion is reduced when more complete inhibition is observed.
Conclusion: These results demonstrate that inhibitors of Aβ self-assembly have the potential to
trap small soluble aggregates resulting in an elevation rather than a reduction of cellular responses.
These findings provide further support that small soluble aggregates possess high levels of
physiological activity and underscore the importance of resolving the effect of Aβ aggregation
inhibitors on aggregate size.
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Background
Alzheimer's disease (AD) is the leading cause of dementia
in the elderly, afflicting a new victim every 71 seconds [1].
AD is characterized by the accumulation of amyloid
plaques in the brain parenchyma and cerebral microvas-
culature. These plaques are comprised primarily of fibrils
formed via self-association of the amyloid-β peptide (Aβ).
The assembly of monomeric Aβ into fibrillar form has
been implicated in the pathogenesis of AD, a premise for-
mally set forth in the amyloid hypothesis [2,3]. In partic-
ular, genetic mutations associated with early onset AD
promote Aβ assembly by either elevating total Aβ produc-
tion or increasing the relative amount of the longer, more
fibrillogenic form of the peptide. Overexpression of these
mutations in transgenic animal models results in an age-
dependent development of amyloid plaques as well as
deficits in reference and working memory [4]. Conse-
quently, inhibition of Aβ self-assembly is under investiga-
tion as a therapeutic strategy for AD. Similarly,
endogenous molecules that are able to regulate Aβ assem-
bly can impact disease progression.
Recent revisions to the amyloid hypothesis implicate a
principal role for soluble Aβ aggregates, including Aβ-
derived diffusible ligands (ADDLs), oligomers, and pro-
tofibrils, in the pathogenesis of AD. Soluble Aβ aggregates
are capable of eliciting a number of responses in neuronal
cell systems, including the impairment of long-term
potentiation, the initiation of synaptic loss, and the alter-
ation of memory function [reviewed in [2,5]]. In addition,
soluble Aβ aggregates have been demonstrated to selec-
tively elicit changes in brain endothelial cells associated
with the increased immune response observed in AD
brain, including the activation of endothelial monolayers
for increased adhesion and subsequent transmigration of
monocyte cells [6] and the stimulation of increases in
endothelial monolayer permeability [7]. Here, a specific
role for small soluble aggregates was implicated by an
inverse relationship between endothelial response and
aggregate size.
Plasma proteins have the potential to mediate AD-linked
inflammatory responses observed in the brain endothe-
lium. A number of plasma proteins are known to bind
various isoforms of Aβ, including Aβ1–40  and Aβ1–42
[reviewed in [8]]. In fact, > 95% of circulating Aβ is bound
by carrier proteins in blood plasma [9,10], with the
majority of Aβ bound to serum albumin [10]. Several
plasma proteins, including serum albumin, are also asso-
ciated with amyloid plaques deposited in the brain
[reviewed in [11]].
Interactions between Aβ and plasma proteins have been
observed to inhibit Aβ assembly [reviewed in [8]]. Sixty
percent of the inhibitory activity present within human
plasma has been ascribed to serum albumin [12], and this
inhibitory activity has been suggested to account for the
lack of Aβ fibril deposition in the periphery [12,13].
Serum albumin has been shown to inhibit the aggregation
of Aβ1–40 and Aβ1–42 monomer [12] as well as the incorpo-
ration of monomeric peptide into Aβ1–40 and Aβ1–42 fibrils
[12], Aβ12–28 oligomers [13], and tissue sections isolated
from AD brain [12]. Some studies suggest that serum
albumin preferentially binds small Aβ aggregates [12,13].
Trapping these small soluble aggregates has the potential
to increase Aβ stimulation of brain endothelium.
In the current study, we examine the relationship between
the in vitro inhibitory activity of serum albumin and the
activation of endothelial monolayers by inhibited Aβ1–40
aggregate preparations. An inhibitory role for bovine
serum albumin (BSA) in both the formation and subse-
quent growth of Aβ1–40  aggregates is confirmed and
shown to be dose-dependent. The stoichiometry observed
for BSA inhibition of aggregate growth suggests that BSA
is capable of binding Aβ1–40 aggregates. Furthermore, the
characterization of Aβ1–40 aggregates via dynamic light
scattering (DLS) demonstrates that BSA inhibition of Aβ1–
40  aggregate formation from monomeric peptide can
increase populations of small soluble aggregate species.
Inhibition of Aβ1–40  aggregate formation from mono-
meric peptide is not paralleled by a dose-dependent
decrease in Aβ-induced activation of endothelial cells for
monocyte adhesion. Instead, endothelial monolayer acti-
vation is enhanced when intermediate levels of inhibitor
activity lead to an increase in the number of small soluble
Aβ1–40 aggregates. These results demonstrate that soluble
Aβ aggregates trapped by inhibitors of Aβ self-assembly
can enhance physiological responses associated with AD.
Methods
Materials
Aβ1–40 was purchased from AnaSpec (San Jose, CA) or W.
M. Keck Biotechnology Resource Laboratory (New Haven,
CT). BSA was obtained from EMD Chemicals (Gibbs-
town, NJ). Thioflavin T, RPMI 1640 medium, fetal bovine
serum (FBS), hydrocortisone, gelatin, and Calcein-AM
were obtained from Sigma (St. Louis, MO). CS-C Medium
and other CS-C culture reagents were obtained from Cell
Systems (Kirkland, WA). Collagen was obtained from
PureCol INAMED (Fremont, CA).
Preparation of Aβ1–40 monomer and fibril
Lyophilized Aβ1–40 was stored desiccated at -20°C until
preparation of monomer or fibril as described previously
[6]. Briefly, Aβ1–40 was reconstituted (2 mg/ml) in 50 mM
NaOH and pre-existing aggregates were removed by size
exclusion chromatography on a Superdex 75 HR10/30
column (GE Healthcare, Piscataway, NJ) equilibrated in
40 mM Tris-HCl (pH 8.0). Isolated monomer was used
fresh or stored at 4°C for up to 24 h. To prepare fibrils,
isolated monomeric Aβ1–40 (100–200 μM) was agitatedJournal of Biological Engineering 2009, 3:5 http://www.jbioleng.org/content/3/1/5
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vigorously at 25°C in the presence of 250 mM NaCl and
40 mM Tris-HCl (pH 8.0) for 24–30 h. Fibrils were evalu-
ated via thioflavin T fluorescence, isolated via centrifuga-
tion (15 min, 18,000 × g), resuspended in 40 mM Tris-
HCl (pH 8.0), and stored at 4°C for up to 1 week.
Detection of Aβ1–40 aggregates using thioflavin T
As described previously [6], thioflavin T fluorescence was
monitored for samples containing 10 μM thioflavin T
solution in 40 mM Tris-HCl (pH 8.0). Fluorescence was
measured on an LS-45 luminescence spectrometer (Per-
kin-Elmer, Waltham, MA) with excitation at 450 nm. Flu-
orescence (F) was taken as the integrated area under the
emission curve (470–500 nm) with baseline (thioflavin T,
BSA) subtraction.
Aβ1–40 monomer aggregation assay
Aβ1–40 monomer was diluted to 20 μM in 40 mM Tris-HCl
(pH 8.0) containing 150 mM NaCl and incubated in the
absence (control) or presence of 20–80 μM BSA at 25°C
and under vigorous agitation (vortex, 500 rpm). Reaction
progress was monitored via thioflavin T fluorescence fol-
lowing dilution of an aliquot into 10 μM thioflavin T, and
results are reported as the change in thioflavin T fluores-
cence (ΔF) with time. Subsequent to the final fluorescence
measurement, aggregate size was assessed for undiluted
samples via hydrodynamic radius (RH) measurements.
Experiments in which thioflavin T fluorescence and RH
were measured for BSA subjected to aggregation condi-
tions in the absence of Aβ1–40 monomer served as a nega-
tive control and ascertained the negligible contribution of
BSA to these signals.
Determination of Aβ1–40 aggregate size using DLS
As described previously [6], aggregate size was assessed via
RH measurements using a DynaPro MSX DLS instrument
(Wyatt Technology, Santa Barbara, CA) to assimilate auto-
correlated light intensity data for calculation of transla-
tional diffusion coefficients that could be converted to RH
using the Stokes-Einstein equation. RH was assessed from
the intensity-weighted histogram calculated via data regu-
lation with Dynamics software (Wyatt Technology).
Aβ1–40 fibril elongation assay
Aβ1–40 fibrils were diluted in 40 mM Tris-HCl (pH 8.0)
containing thioflavin T and incubated for 15 min in the
absence (control) or presence of BSA. To initiate growth,
Aβ1–40 monomer was added for final concentrations of 40
μM monomer, 2 μM fibril, 0–10 μM BSA, and 10 μM thio-
flavin T. Reactions were incubated at 25°C without agita-
tion, and the incorporation of monomer into growing
fibrils was monitored via thioflavin T fluorescence. Exper-
iments in which thioflavin T fluorescence of 40 μM Aβ1–40
monomer was monitored in the absence of fibrils con-
firmed that monomer self-assembly did not occur under
these experimental conditions. In addition, experiments
in which thioflavin T fluorescence of 2 μM Aβ1–40 fibrils
was monitored without addition of monomer served as
negative controls and reflected the stability of fibrils.
Results are reported as the change in thioflavin T fluores-
cence (ΔF) with time, and elongation rates were deter-
mined by linear regression of this data.
Cell culture
ACBRI 376 primary human brain microvascular endothe-
lial cells (HBMVECs) (Cell Systems, Kirkland, WA) and
the human pre-monocytic cell line THP-1 (American Type
Culture Collection, Rockville, MD) were maintained and
prepared for experiments as described previously [6].
Endothelial cells (passage 4–8) were seeded (5 × 105–6 ×
105 cells/ml) onto coated (2.0% gelatin, 100 μg/ml colla-
gen) 96-well flat-bottom culture plates and sustained
until confluence in CS-C Serum Free Medium supple-
mented with hydrocortisone (550 nM). THP-1 cells main-
tained in supplemented RPMI 1640 medium containing
10% FBS were fluorescently labelled for adhesion experi-
ments via incubation with Calcein-AM followed by resus-
pension in Dulbecco's PBS (D-PBS) (2 × 105 cells/ml).
Adhesion assay
Confluent HBMVEC monolayers were treated for 24 h
with Aβ1–40 monomer aggregated in the absence (positive
control) or presence of BSA. Reaction products were
diluted into culture medium containing hydrocortisone
for a final Aβ1–40 concentration of 5 μM. Parallel treatment
with an equivalent dilution of BSA or buffer served as neg-
ative controls. As described previously for adhesion assays
[6], activated monolayers were washed and incubated
with Calcein-labelled THP-1 cells (2 × 104cells/well) for
30 min (37°C, 5% CO2). Nonadherent cells were
removed by gentle washing (D-PBS). The number of
adherent cells was assessed by Calcein fluorescence
employing a Synergy 2 microplate reader (BioTek Instru-
ments, Inc., Winooski, VT) equipped with an excitation
filter of 485 ± 10 nm and an emission filter of 528 ± 10
nm and using baseline (D-PBS) subtraction. Results are
reported as the percentage of adherent cells
[(100%)·(Cellsadherent/Cellsinitial)].
Statistical analysis
Statistical analysis was performed with a one-way ANOVA
using GraphPad Prism 5 software (San Diego, CA). Dun-
nett's test was used for multiple comparisons. P < 0.05 was
considered significant. Linear regression was assessed
using the coefficient of determination, r2.
Results
BSA inhibits aggregation of Aβ1–40 monomer
To assess the effect of BSA on Aβ1–40 fibril assembly from
monomeric peptide, monomer aggregation was induced
by continuous agitation in the presence of ratios of BSA to
Aβ1–40 monomer ranging from equimolar to 4-fold excess.Journal of Biological Engineering 2009, 3:5 http://www.jbioleng.org/content/3/1/5
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The formation of aggregated β-sheet structure was moni-
tored using thioflavin T fluorescence. To ensure that the
presence of BSA did not impede detection of Aβ aggre-
gates, it was confirmed that the thioflavin T fluorescence
of pre-formed Aβ1–40 fibrils was not reduced in the pres-
ence of BSA. These results indicate that BSA does not com-
pete with thioflavin T for binding to fibrils nor does it
sequester thioflavin T to prevent its binding to fibrils.
As shown in Figure 1, 20 μM Aβ1–40 monomer incubated
in the absence of BSA exhibited the characteristic lag,
indicative of nucleus formation, followed by rapid aggre-
gate growth and concluding with a plateau as equilibrium
was reached. BSA-induced changes in Aβ1–40 monomer
aggregation were assessed by evaluating both extension of
the lag time and reduction of the plateau fluorescence
level. When BSA was present at equimolar concentrations
with Aβ1–40 monomer, the lag time was nearly doubled
(Figure 1, Table 1), suggesting that BSA can intervene at
early points along the self-assembly pathway. As the con-
centration of BSA was increased to a level 2-fold in excess
of Aβ1–40 monomer, the lag time was further extended by
almost 2.5-fold and the equilibrium plateau was reduced,
indicating that at higher concentrations BSA can reduce
the quantity of aggregated Aβ. When Aβ1–40 monomer was
agitated in the presence of a 4-fold excess of BSA, nearly
complete inhibition was observed over the 4.5 h period.
BSA subjected to aggregation conditions in the absence of
Aβ1–40 monomer exhibited negligible change in thioflavin
T fluorescence. These results illustrate the ability of BSA to
abrogate Aβ1–40 monomer aggregation at concentrations
in excess of Aβ1–40 monomer and further demonstrate the
dose-dependent nature of this inhibition as BSA concen-
trations approach stoichiometric ratios with Aβ1–40.
BSA inhibits growth of Aβ1–40 fibrils via monomer addition
To determine whether BSA is capable of interacting with
pre-formed Aβ1–40 aggregates to inhibit later stages of Aβ1–
40 assembly, the growth of Aβ1–40 fibrils was assessed fol-
lowing pre-incubation in the presence of BSA at ratios of
BSA to Aβ1–40 fibril ranging from substoichiometric to 5-
fold excess, where fibril concentrations are expressed in
monomer units. Fibril growth was induced via addition of
Aβ1–40 monomer, and the incorporation of monomer into
growing fibrils was monitored as the change in thioflavin
T fluorescence. Thioflavin T may itself act as both an indi-
cator and an inhibitor of Aβ self-assembly. However, at
stoichiometric ratios that exceed those included within
fibril elongation reactions thioflavin T has been observed
to have no effect upon the formation of Aβ fibrils from
monomeric peptide [14]. In addition, the absence of
inhibitory activity by thioflavin T within the Aβ fibril
elongation assay has been experimentally confirmed for
the conditions employed (data not shown).
As shown in Figure 2, steady growth was observed when 2
μM Aβ1–40 fibril was incubated with 40 μM Aβ1–40 mono-
mer (Figure 2). This uninhibited rate of fibril growth was
compared to the rate of growth observed in the presence
of BSA to determine the extent of inhibition. Aβ1–40 fibrils
pre-incubated in the presence of BSA at a level 5-fold in
excess of monomeric units within Aβ1–40 fibrils exhibited
a much slower rate of growth (Figure 2) and therefore sig-
nificant inhibition (Table 1), confirming that BSA is able
to prevent the addition of Aβ1–40 monomer to pre-formed
Aβ1–40 fibrils. Pronounced inhibition was also evident
when BSA was present at concentrations equimolar to
Table 1: Dose-dependent inhibition of Aβ1–40 monomer 
aggregation and fibril growth in the presence of BSA a
Reaction Monomer Aggregation c Fibril Growth d
(BSA:Aβb)L a g  T i m e
(fold increase)
Plateau
(% reduction)
Growth Rate
(% inhibition)
1:4 --- --- 49 ± 11 *
1:1 1.9 ± 0.4 6 ± 6 61 ± 17 *
2:1 2.4 ± 0.6 34 ± 18 ---
4:1 > 7 * 97 ± 2 * ---
5:1 --- --- 80 ± 11 *
a Parameters are expressed as mean ± SE, n = 3.
b Aβ1–40 fibril concentrations are expressed in monomer units.
c Monomer aggregation was measured as in Figure 1.
d Fibril growth was measured as in Figure 2.
* p < 0.05 compared to control.
Effect of BSA on Aβ1–40 monomer aggregation Figure 1
Effect of BSA on Aβ1–40 monomer aggregation. Aβ1–40 
monomer was diluted to 20 μM in buffer containing 150 mM 
NaCl and 40 mM Tris-HCl (pH 8.0) and incubated alone 
(control, [white circle]) or in the presence of 20 μM [black 
square], 40 μM [black triangle], or 80 μM [black diamond] 
BSA. Aggregation of monomer was induced by continuous 
agitation and monitored using thioflavin T fluorescence. 
Results are representative of three independent experi-
ments.
100 200 300 0
0
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monomeric units within Aβ1–40 fibrils. Further reduction
in the concentration of BSA to a substoichiometric ratio of
1:4 BSA:Aβ1–40 fibril continued to inhibit fibril growth at
lower but still significant levels. These results illustrate the
ability of BSA to modulate the growth of pre-formed Aβ1–
40 aggregates in a dose-dependent manner and, in contrast
to BSA inhibition of monomer aggregation, demonstrate
the strength of this inhibition at substoichiometic BSA
concentrations.
BSA inhibition of Aβ1–40 aggregate assembly modulates 
physiological activity
To assess the effect of BSA upon the physiological activity
of Aβ1–40 aggregates, brain endothelial cells, which are in
direct and continuous contact with circulating serum pro-
teins, were selected. Aβ1–40 has been previously observed
to stimulate HBMVECs for increased adhesion of both
THP-1 monocytes [6,15,16] and primary human periph-
eral blood monocytes [6,16] via a mechanism that
involves Aβ recognition of the receptor for advanced gly-
cation end products [15,16]. The ability of BSA to attenu-
ate this Aβ-induced adhesion in HBMVECs was explored.
When HBMVEC monolayers were treated with 5 μM Aβ1–
40 aggregates formed in the absence of BSA, a 2.3-fold
increase in adhesion of THP-1 monocytes relative to
untreated control monolayers was observed (Figure 3).
This result is similar to that reported previously [6]. Aβ1–
40 aggregates formed in the presence of a 2-fold excess of
BSA stimulated an even more pronounced 2.9-fold
increase in adhesion of THP-1 monocytes, despite the
decreased thioflavin T fluorescence observed under these
aggregation conditions (Figure 1). In contrast, when Aβ1–
40 aggregates were formed in the presence of a 4-fold
excess of BSA, a smaller increase in THP-1 adhesion of
only 1.5-fold was observed. BSA treatment of endothelial
monolayers in the absence of Aβ made an insignificant
contribution to the observed changes in adhesion. These
results demonstrate that inhibition of in vitro Aβ1–40 mon-
omer aggregation by BSA is not paralleled by a dose-
dependent decrease in physiological activity.
Physiological activity of Aβ1–40 aggregates correlates with 
aggregate size
Previous studies revealed that the size of Aβ1–40 aggregates
determines their ability to stimulate endothelial monol-
ayers for monocyte adhesion. The most pronounced
increases in adhesion were observed for small soluble
aggregates exhibiting RH values of 20–40 nm. Physiologi-
cal activity decreased as aggregate size increased to 100
Effect of BSA on Aβ1–40 fibril growth via monomer addition Figure 2
Effect of BSA on Aβ1–40 fibril growth via monomer 
addition. Aβ1–40 fibril in 40 mM Tris-HCl (pH 8.0) containing 
10 μM thioflavin T was pre-incubated for 15 min alone or in 
the presence of BSA. Solutions were then diluted for final 
concentrations of 2 μM Aβ1–40 fibril (concentration 
expressed in monomer units) with 0 μM (control, [white cir-
cle]), 0.5 μM [black square], 2 μM [black triangle], or 10 μM 
[black diamond] BSA, and 40 μM Aβ1–40 monomer was added 
to induce fibril growth. Incorporation of Aβ1–40 monomer 
into fibrillar structures was monitored using thioflavin T fluo-
rescence. Linear regression (solid lines) was performed to 
determine growth rates. Results are representative of three 
independent experiments.
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Effect of BSA inhibition of Aβ1–40 monomer aggregation on  endothelial adhesion in HBMVECs Figure 3
Effect of BSA inhibition of Aβ1–40 monomer aggrega-
tion on endothelial adhesion in HBMVECs. HBMVEC 
monolayers grown to confluence in 96-well plates were stim-
ulated via 24 h incubation. Confluent monolayers were incu-
bated alone (-CONT) or with 5 μM Aβ1–40 aggregates 
formed in the absence (+CONT) or presence of BSA at con-
centrations 2-fold (BSA, 2X) or 4-fold (BSA, 4X) in excess of 
Aβ1–40 monomer. Activated monolayers were washed and 
adhesion of Calcein-labelled THP-1 cells (2 × 104 cells/well) 
was assessed via fluorescence as described in Materials and 
Methods. * p < 0.05, ** p < 0.01, *** p < 0.001. Results are 
representative of three independent experiments performed 
with six repetitions. Error bars represent SEM.
-CONT +CONT BSA, 2X BSA, 4X
0
20
40
***
***
**
***
*
%
 
A
d
h
e
s
i
o
nJournal of Biological Engineering 2009, 3:5 http://www.jbioleng.org/content/3/1/5
Page 6 of 8
(page number not for citation purposes)
nm, and aggregates exceeding 100 nm increased endothe-
lial adhesion only modestly [6]. A similar inverse correla-
tion was also observed for Aβ1–40  stimulation of
endothelial permeability [7]. Thus, it was speculated that
the differential effect of BSA on the physiological activity
of Aβ1–40 aggregate preparations might be related to differ-
ences in the resulting aggregate size.
DLS was employed to evaluate RH for aggregates formed in
the presence and absence of BSA as well as BSA subjected
to aggregation conditions in the absence of Aβ1–40 mono-
mer. Aβ1–40 monomer incubated in the absence of BSA
yielded aggregates with an RH of 140 nm (Figure 4B) that
produced, as expected, a moderate but pronounced
increase in endothelial adhesion (Figure 3). While addi-
tion of BSA at a concentration 2-fold in excess of Aβ1–40
monomer yielded less aggregated peptide (Figure 1), these
aggregates exhibited a smaller RH of 34 nm (Figure 4C)
and were thus capable of eliciting higher physiological
activity (Figure 3). In contrast, Aβ1–40 aggregations per-
formed in the presence of a 4-fold excess of BSA yielded
little aggregated peptide (Figure 1) and exhibited a hydro-
dynamic radius of 3.4 nm (Figure 4D). This peak may be
ascribed to BSA, as an identical peak was observed when
BSA was subjected to aggregation conditions in the
absence of Aβ1–40 monomer (Figure 4A). Due to the expo-
nential relationship between scattered light and aggregate
size, this BSA peak would obscure detection of Aβ mono-
mer or aggregates exhibiting RH smaller than 3.4 nm.
Thus, it may be deduced that following aggregation in the
presence of a 4-fold excess of BSA, Aβ1–40 exists primarily
as monomeric or oligomeric structures. However, a lower
intensity peak at 22 nm (Figure 4D) indicates the presence
of a small population of soluble aggregates with high
physiological activity, which likely accounts for the mod-
est increase in adhesion observed for this Aβ1–40 aggregate
preparation (Figure 3). Together, these results demon-
strate that the enhanced physiological activity observed
for partially inhibited monomer aggregations correlates
with an increase in the population of small soluble Aβ1–40
aggregates.
Discussion
Aβ has the opportunity to interact in vivo with endog-
enous proteins, peptides, and small molecules prior to
and during its self-assembly to form fibrillar aggregates
which deposit in the brain parenchyma and cerebral
microvasculature and become hallmarks of AD. Implica-
tions that small soluble aggregation intermediates may
play a principal role in disease progression leave open the
possibility that endogenous molecules which intervene at
intermediate stages of self-assembly could elevate physio-
logical activity. Several serum proteins, including serum
albumin, have been observed to bind Aβ and inhibit the
formation of fibrils [reviewed in [8]]. These proteins may
Effect of BSA inhibition of Aβ1–40 monomer aggregation on  aggregate size distribution Figure 4
Effect of BSA inhibition of Aβ1–40 monomer aggrega-
tion on aggregate size distribution. Aβ1–40 monomer 
aggregations were performed as in Figure 1 for 20 μM Aβ1–40 
monomer in the presence of 0 μM (panel B, control), 40 μM 
(panel C), or 80 μM (panel D) BSA. In addition, 80 μM BSA 
was subjected to aggregation conditions in the absence of 
Aβ1–40 monomer (panel A). DLS was employed to determine 
RH distributions. Results are presented as intensity-weighted 
histograms derived from data regularization with Dynamics 
Software (Wyatt Technology). Results are representative of 
two independent experiments.
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influence Aβ activation of endothelial monolayers, a
response which is specific for small soluble Aβ aggregates
[6,17]. In the current study, we provide evidence that par-
tial inhibition of Aβ1–40 aggregate assembly by BSA can
enhance Aβ1–40 stimulation of endothelial monolayers for
monocyte adhesion as a result of an increase in the
number of small soluble aggregates.
Other studies have reported inhibition of Aβ aggregate
assembly by serum albumin. Bohrmann et al. observed
complete inhibition of Aβ1–40  monomer aggregation
when human serum albumin (HSA) was present at an 11-
fold excess [12] and a dose-dependent inhibition by both
BSA and HSA for the incorporation of Aβ1–40 or Aβ1–42
monomer into immobilized fibrils [12]. Using solution
NMR to facilitate atomic resolution of Aβ monomer and
oligomer, Milojevic et al. demonstrated that the presence
of HSA retarded the addition of monomeric Aβ12–28 to
high molecular weight oligomers [13]. In the current
study, dose-dependent BSA inhibition of both the forma-
tion of Aβ1–40 aggregates from monomeric peptide and
the growth of fibrillar Aβ1–40 aggregates was examined to
further understand the stoichiometry of these interac-
tions. The decreasing inhibitory action observed in mon-
omer aggregation assays as albumin reached a 1:1 ratio
with monomeric Aβ1–40 (Figure 1, Table 1) indicates that
BSA may interact with either Aβ1–40 monomer or oligom-
ers containing a small number of monomeric subunits.
Some studies have reported that HSA binds Aβ1–40 and
Aβ1–42 at a 1:1 ratio [9,18] with Kd of 5–13.5 μM [9,18]
and 10.5 μM [9,18], respectively, suggesting that serum
albumin may recognize monomeric Aβ. However, other
studies have reported that BSA and HSA are incapable of
binding monomeric Aβ1–40 and Aβ1–28 but instead recog-
nize aggregated forms of the peptide [12,13], including
oligomers [13].
The observed inhibition of Aβ1–40 fibril growth by mono-
mer addition could likewise result either from the trap-
ping of monomeric Aβ1–40 by BSA or from the blocking of
sites for monomer addition via binding of BSA to Aβ1–40
fibrils. A dominant contribution of the latter mechanism
is implicated by the pronounced inhibition of monomer
addition to fibrils when Aβ1–40 monomer concentrations
(40 μM) significantly exceed BSA levels (0.5 μM). Further-
more, the inhibition of Aβ1–40 fibril growth at substoichi-
ometric ratios of BSA to monomeric units within Aβ1–40
fibrils (Figure 2, Table 1) combined with the previously
reported micromolar affinity of serum albumin for Aβ
[9,18] suggests that the binding of BSA to individual mon-
omer units within Aβ1–40 fibril structures is not required
for the inhibition of Aβ1–40 fibril elongation. Instead, BSA
may bind aggregates at selected sites, among which are
those that prevent subsequent addition of monomeric
peptide. Hydrophobic interactions have been identified
as one of the principal driving forces in the assembly of Aβ
aggregates [19]. Serum albumin possesses multiple hydro-
phobic binding domains [20]. It is therefore reasonable to
speculate that BSA may prevent the addition of monomer
to fibrils by capping exposed hydrophobic sites. A similar
hypothesis was proposed by Milojevic et al. to explain the
arrest of monomer-oligomer exchange following the pref-
erential binding of HSA to high molecular weight oligom-
ers [13].
In solutions of newly formed aggregation intermediates,
the ensuing effect of such strategic capping may be the
trapping of small soluble aggregates that display a high
physiological activity. Trapping of small aggregates has
been observed for other molecules that inhibit Aβ assem-
bly, including naphthalene sulfonates [21], inositol [22],
calmidazolium chloride [23], an antibody recognizing
Aβ1–11 [24], and submicellar concentrations of sodium
dodecyl sulfate [25]. In the current study, both thioflavin
T fluorescence and DLS were employed to illustrate that
the relative ratio of inhibitor to monomeric Aβ1–40 deter-
mines both the quantity (Figure 1) and size (Figure 4) of
aggregates trapped. As expected, uninhibited reactions
allowed the formation of significant quantities of large
Aβ1–40 aggregates and complete inhibition yielded prima-
rily monomeric or oligomeric Aβ1–40. In contrast, interme-
diate levels of inhibition by BSA led to the accumulation
of soluble aggregation intermediates. Moreover, this accu-
mulation was paralleled by an increase in Aβ stimulation
of endothelial monolayers for monocyte adhesion (Figure
3). Some extent of this observed stimulation might be
simply explained by the kinetic reversibility of binding
between BSA and Aβ1–40 aggregates. However, the accu-
mulation of small aggregate species is likely responsible
for the augmented stimulation of endothelial monolayers
relative to that observed for Aβ1–40 aggregates prepared in
the absence of BSA. Aβ aggregate size has been shown pre-
viously to correlate inversely with the ability of aggregates
to stimulate endothelial monolayers for monocyte adhe-
sion [6] and permeability [7]. These results further dem-
onstrate that small aggregates formed as a result of
trapping by an inhibitor also exhibit a higher physiologi-
cal activity. Conversely, Pallitto et al. observed a decrease
in neurotoxicity when Aβ1–39 was incubated in the pres-
ence of a small peptide capable of accelerating aggregation
and increasing aggregate size [26].
Conclusion
Results presented within this study support implications
that small soluble Aβ aggregates may play a principal role
in AD pathogenesis [reviewed in [2,5]] and emphasize the
danger of extrapolating in vitro Aβ inhibition data to
reductions in physiological activity. The trapping of small
soluble aggregates by both endogenous inhibitors, such as
serum albumin, as well as synthetic compounds can leadJournal of Biological Engineering 2009, 3:5 http://www.jbioleng.org/content/3/1/5
Page 8 of 8
(page number not for citation purposes)
to an undesired increase in physiological activity. Such
potential consequences will be critical to consider in the
future design of therapeutic agents targeted at inhibition
of Aβ assembly.
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